News
HanchorBio Doses First Patient in Taiwan in Phase 1 Trial of HCB301
HanchorBio today announced that the first patient in Taiwan has been dosed in HCB301-101, the Company’s ongoing first-in-human Phase 1 clinical study of HCB301.
Apr 08, 2026
Read more
HanchorBio Signals “Backbone” Potential for HCB101 as SAB Aligns on Gastric Cancer Registrational Path
HanchorBio reported outcomes from its recent Scientific Advisory Board (SAB) meeting, highlighting a shift from platform validation to asset-level positioning and registrational strategy.
Apr 03, 2026
Read more
HanchorBio Reports Early Taiwan IIT Signal in 2L CRC With Sustained Disease Control Beyond 37 Weeks
HanchorBio today announced early findings from an ongoing investigator-initiated trial (IIT) in Taiwan evaluating HCB101-based combination therapy in patients with second-line colorectal cancer (CRC).
Apr 03, 2026
Read more
HanchorBio Reports Preliminary First-Line HER2+ Gastric Cancer Data for HCB101, Demonstrating 83.3% ORR
HanchorBio's early clinical observations show deep tumor reductions across dose levels, supporting continued development in combination settings.
Apr 01, 2026
Read more
HanchorBio Presents First Dedicated HCB101 Head and Neck Cancer Data in Oral Presentation at ICHNO 2026
HanchorBio announced the first dedicated presentation of HCB101 clinical data in head and neck squamous cell carcinoma (HNSCC) in an oral presentation at ICHNO 2026 (the 10th International Congress on Innovative Approaches in Head and Neck Oncology), a joint ESTRO, EHNS, and ESMO congress, in Seville, Spain.
Mar 20, 2026
Read more
HanchorBio Expands Global Patent Protection for HCB101 with Taiwan Grant
Taiwan grant adds to issued patents in the United States and Japan, further strengthening HCB101’s cross-border IP estate and supporting long-term development and partnering strategy.
Mar 17, 2026
Read more
HanchorBio Presents First Public Clinical Data for HCB301, a Tri-Specific Innate Checkpoint Molecule, at ESMO-TAT 2026
HanchorBio, Inc. announced the presentation of first-in-human clinical data for HCB301 at the ESMO Targeted Anticancer Therapies (TAT) Congress 2026 in Paris, France.
Mar 16, 2026
Read more
HanchorBio Highlights Advancing HCB101 Clinical Program Across Monotherapy and Combination Settings at ESMO-TAT 2026
HanchorBio announced the presentation of updated clinical data for HCB101 at the ESMO Targeted Anticancer Therapies (TAT) Congress 2026 in Paris, France.
Mar 16, 2026
Read more
HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress
HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress Early clinical data show 100% ORR at 5.12 mg/kg, 100% DCR across doses, and dose-dependent tumor shrinkage; the 12 mg/kg cohort remains ongoing HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology […]
Mar 05, 2026
Read more
HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026
HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026 Monotherapy and multi-regimen combination data demonstrate a cytopenia-sparing safety profile, robust CD47 receptor occupancy, and encouraging dose-dependent antitumor activity HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today presented new clinical and translational data on HCB101, its […]
Feb 19, 2026
Read more